New concepts and approaches to stroke prevention in the new European Society of Cardiology guidelines for the management of atrial fibrillation

References

• Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA285, 2370–2375 (2001).
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA); endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J.31(19), 2369–2429 (2010).
   PubMed Web of Science ®Google Scholar
• Rietbrock S, Plumb JM, Gallagher AM, van Staa TP. How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. Thromb. Haemost.101, 527–534 (2009).
   PubMed Web of Science ®Google Scholar
• Tay KH, Lip GY, Lane DA. Atrial fibrillation and stroke risk prevention in real-life clinical practice. Thromb. Haemost.101, 415–416 (2009).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med.146, 857–867 (2007).
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am. J. Med.123, 638–645.e4 (2010).
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA290(20), 2685–2692 (2003).
   PubMed Web of Science ®Google Scholar
• Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe? Thromb. Haemost.104, 45–48 (2010).
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest137, 263–272 (2010).
   PubMed Web of Science ®Google Scholar
• Lane DA, Lip GY. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb. Haemost.101, 802–805 (2009).
   PubMed Web of Science ®Google Scholar
• Conway DS, Lip GY. Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am. J. Cardiol.93(11), 1422–1425, A10 (2004).
   PubMed Web of Science ®Google Scholar
• Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis. J. Am. Coll. Cardiol.56, 827–837 (2010).
   PubMed Web of Science ®Google Scholar
• Hylek EM. Contra: ‘Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation’. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb. Haemost.100, 16–17 (2008).
   PubMed Web of Science ®Google Scholar
• Mant JW. Pro: ‘Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation’. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation. Thromb. Haemost.100, 14–15 (2008).
   PubMed Web of Science ®Google Scholar
• Gorin L, Fauchier L, Nonin E et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb. Haemost.103, 833–840 (2010).
   PubMed Web of Science ®Google Scholar
• Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb. Haemost.103, 683–685 (2010).
   PubMed Web of Science ®Google Scholar
• van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke40, 1410–1416 (2009).
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FD, Fletcher K et al.; BAFTA Investigators; Midland Research Practices Network (MIDREC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet370, 493–503 (2007).
   PubMed Web of Science ®Google Scholar
• Pengo V, Cucchini U, Denas G et al. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. Thromb. Haemost.103, 442–449 (2010).
   PubMed Web of Science ®Google Scholar
• Singer DE, Chang Y, Fang MC et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ. Cardiovasc. Qual. Outcomes2, 297–304 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Eikelboom J et al.; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation118, 2029–2037 (2008).
   PubMed Web of Science ®Google Scholar
• Hughes M, Lip GY; Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM100, 599–607 (2007).
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest DOI: 10.1378/chest.10-0134 (2010) (Epub ahead of print).
   Google Scholar
• Nieuwlaat R, Capucci A, Camm AJ et al.; European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur. Heart J.26, 2422–2434 (2005).
   PubMed Web of Science ®Google Scholar
• Lip GY. Don’t add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. Br. Med. J.336, 614–615 (2008).
   PubMed Web of Science ®Google Scholar
• Lip GY, Huber K, Andreotti F et al.; European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb. Haemost.103, 13–28 (2010).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Hart RG et al.; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med.360, 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Shantsila E, Lip GY, Lane DA. Contra: ‘Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation’. Thromb. Haemost.102, 914–915 (2009).
   PubMed Web of Science ®Google Scholar
• Healey JS. Pro: ‘Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation’. Thromb. Haemost.102, 912–913 (2009).
   PubMed Web of Science ®Google Scholar